Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors

In Vitro Cellular and Developmental Biology - Animal

Volumn 42, Issue 3-4, 2006, Pages 89-95

  Chiriva Internati, Maurizio ^a,b,c,d   Grizzi, Fabio ^e,f   Pinkston, Justin ^a   Morrow, K John ^a   D'Cunha, Nicholas ^b,d   Frezza, Eldo E ^c   Muzzio, Pier Carlo ^h   Kast, W Martin ^g   Cobos, Everardo ^b,d  

^a Department of Microbiology and Immunology ^*  (United States)

^b Internal Medicine and Hematology/Oncology/Bone Marrow Transplant   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^d Southwest Cancer Treatment and Research Center   (United States)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f Michele Rodriguez Foundation   (Italy)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF PADOVA   (Italy)

Author keywords

gamma irradiation; MHC; Multiple myeloma; Radiotherapy; Tumor

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL DIVISION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GAMMA IRRADIATION; GAMMA RADIATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; MULTIPLE MYELOMA; PROTEIN SYNTHESIS; RADIATION DOSE;

ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CELL LINE, TUMOR; FLOW CYTOMETRY; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; GENES, MHC CLASS II; HLA ANTIGENS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MULTIPLE MYELOMA;

EID: 33747616867     PISSN: 10712690     EISSN: None     Source Type: Journal    
DOI: 10.1290/0508054.1     Document Type: Article

References (21)

1. Alexanian, R.; Dimopoulos, M. A.; Hester, J.; Delasalle, K.; Charaplin, R. Early myeloablative therapy for multiple myeloma. Blood 84:4278-4282; 1994.
2. Anichini, A.; Mortarini, R.; Alberti, S., et al. T-cell-receptor engagement and tumor ICAM-1 upregulation are required to bypass low susceptibility of melanoma cells to autologous CTL-mediated lyses. Int J. Cancer 53:994-1001; 1993.
3. Barlogie, B.; Jagannath, S.; Naucke, S., et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 11:1101-1107; 1998.
4. Bortin, M. M.; Truitt, R. L.; Rimm, A. A.; Bach, F. H. Graft-versus-leukemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity. Nature 281:490-491; 1979.
5. Champlin, R. E.; Feig, S. A.; Gale, R. P. Case problems in bone marrow transplantation. I. Graft failure in aplastic anemia: Its biology and treatment. Exp Hematol 12:728-733; 1984.
6. Chiriva-Internati, M.; Du, J.; Cannon, M., et al. Myeloma-reactive allospecific cytotoxic T lymphocytes lyses target cells by the granule exocytosis pathway. Br. J. Haematol 112:410-420; 2001.
7. Crucian, B. E.; Moscinski, L. C.; Androlewicz, M., et al. Assessment of intracellular TAP-1 and TAP-2 in conjunction with surface MHC class I in plasmacells from patients with multiple myeloma. Br. J. Haematol 98:426-432; 1997.
8. Dranoff, G.; Jaffee, E.; Lazenby, A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long&hyhen← sting anti-tumor immunity. Proc Natl Acad. Sci USA 90:3539-3543; 1993.
9. Epstein, J.; Hoover, R.; Kornbluth, J.; Barlogie, B. Biological aspects of multiple myeloma. Baillieres Clin Haematol 8:721-734; 1995.
10. Hall E. J. Time, dose, and fractionation in radiotherapy. In: Radiobiology for the Radiologist, 3nd ed. Philadelphia, PA: J. B. Lippincott Company; 1988:239-259.
11. Harousseau, J. L.; Attal, M.; Divine, M., et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma. Stem Cells 2:129-132; 1995.
12. b in B16 melanoma cells. Cancer Res. 53:1952-1955; 1993.
13. Moscinski, L. C.; Ballester, O. F. Recent progress in multiple myeloma. Hematol Oncol 12:111-123; 1994.
14. Santin, A. D.; Hermonat, P. L.; Ravaggi, A., et al. Effects of irradiation on the expression of major histocompatibility complex 1 antigen and adhesion costimulation molecules ICAM-1 in human cervical cancer. Int J. Radiat Oncol Biol Phys 39:737-742; 1997a.
15. Santin, A. D.; Hermonat, P. L.; Ravaggi, A., et al. Expression and cytokine-mediated modulation of adhesion costimulation molecules ICAM-1 and alfa-3 in human cervical cancer. Int J. Gynecol Cancer 7:273-278; 1997b.
16. Santin, A. D.; Hermonat, P. L.; Ravaggi, A., et al. Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. Cancer 83:2346-2352; 1998.
17. Santin, A. D.; Hiserodt, J. C.; Fruehauf, J., et al. Effects of irradiation on the expression of surface antigens in human ovarian cancer. Gynecol Oncol. 60:468-474; 1996.
18. Taylor, J. L.; Grossberg, S. E. Recent progress in interferon research: Molecular mechanisms of regulation, action, and virus circumvention. Virus Res 15:1-26; 1990.
19. Tricot, G.; Barlogie, B.; Jagannath, S. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 11:4250-4256; 1995.
20. 2+ levels. J. Immunol 149:3872-3880; 1992.
21. Zamai, L.; Rana, R.; Mazzotti, G., et al. Lymphocyte binding to K562 cells: Effects of target cell irradiation and correlation with ICAM-1 and LFA-3 expression. Eur J. Histochem 38:53-60; 1994.